What's Happening?
Augurex Life Sciences will present new data from clinical studies at the American College of Rheumatology Convergence 2025 in Chicago. The presentations will focus on the use of autoantibodies to 14-3-3eta in diagnosing axial spondyloarthritis. Augurex aims to provide new tools to eliminate diagnostic delays in axSpA, enabling earlier access to therapies. The company will showcase its diagnostic solutions, including JOINTstat and SPINEstat, which are available in Canada and Great Britain.
Why It's Important?
Augurex's presentations at ACR Convergence 2025 highlight the company's commitment to advancing diagnostic solutions for autoimmune disorders. By providing tools for early identification and diagnosis, Augurex aims to improve patient outcomes and optimize treatment options. The focus on axial spondyloarthritis addresses a significant unmet need in the medical community, offering potential benefits for patients and healthcare providers. The event provides a platform for Augurex to share its innovative approaches and engage with the rheumatology community.
